Physician profile
Christopher Michael Hansen
NPI 1306821293
$2,228.33
in general payments reported to CMS, 2019-2025
23 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.24 · 2021: $35.26 · 2022: $145 · 2023: $286 · 2024: $698 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $457.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $268.62 | 2020-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $255.78 | 2022-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $154.07 | 2025 | Auvelity |
| Pfizer INC. | $149.76 | 2024-2025 | |
| Boston Scientific Corporation | $149.72 | 2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $140.56 | 2024-2025 | Airsupra |
| Amgen INC. | $138.96 | 2022-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $76.75 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $65.43 | 2024-2025 | Trintellix |
| Abbvie INC. | $64.61 | 2021-2025 | |
| Astellas Pharma US INC | $54.41 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.66 | 2022-2025 | Jardiance |
| Abbott Laboratories | $32.86 | 2023-2024 | Freestyle Libre 3 |
| Seqirus USA INC | $32.22 | 2025 | Fluad, Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.83 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.65 | 2023 | Rexulti |
| Shield Therapeutics INC | $21.10 | 2025 | |
| Eisai INC. | $18.82 | 2025 | |
| Sumitomo Pharma America, INC. | $17.12 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $14.59 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $13.42 | 2022 | |
| Phathom Pharmaceuticals, INC. | $1.82 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.